Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

C. Le Péchoux, A. Laplanche, C. Faivre-Finn, T. Ciuleanu, R. Wanders, D. Lerouge, R. Keus, M. Hatton, G. M. Videtic, S. Senan, Aaron Wolfson, R. Jones, R. Arriagada, E. Quoix, A. Dunant

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Background: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). Patients and methods: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. Results: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). Conclusion: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.

Original languageEnglish
Pages (from-to)1154-1163
Number of pages10
JournalAnnals of Oncology
Volume22
Issue number5
DOIs
StatePublished - May 5 2011

Fingerprint

Cranial Irradiation
Quality of Life
Organizations
Research
Small Cell Lung Carcinoma
Neoplasms
Brain
Neoplasm Metastasis
Therapeutics
Radiation Oncology
Memory Disorders
Standard of Care
Cognition
Leg
Radiotherapy
Logistic Models
Communication
Survival
Incidence

Keywords

  • Limited disease
  • Neurocognitive evaluation
  • Phase III clinical trial
  • Prophylactic cranial irradiation
  • Quality of life
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). / Le Péchoux, C.; Laplanche, A.; Faivre-Finn, C.; Ciuleanu, T.; Wanders, R.; Lerouge, D.; Keus, R.; Hatton, M.; Videtic, G. M.; Senan, S.; Wolfson, Aaron; Jones, R.; Arriagada, R.; Quoix, E.; Dunant, A.

In: Annals of Oncology, Vol. 22, No. 5, 05.05.2011, p. 1154-1163.

Research output: Contribution to journalArticle

Le Péchoux, C, Laplanche, A, Faivre-Finn, C, Ciuleanu, T, Wanders, R, Lerouge, D, Keus, R, Hatton, M, Videtic, GM, Senan, S, Wolfson, A, Jones, R, Arriagada, R, Quoix, E & Dunant, A 2011, 'Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)', Annals of Oncology, vol. 22, no. 5, pp. 1154-1163. https://doi.org/10.1093/annonc/mdq576
Le Péchoux, C. ; Laplanche, A. ; Faivre-Finn, C. ; Ciuleanu, T. ; Wanders, R. ; Lerouge, D. ; Keus, R. ; Hatton, M. ; Videtic, G. M. ; Senan, S. ; Wolfson, Aaron ; Jones, R. ; Arriagada, R. ; Quoix, E. ; Dunant, A. / Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). In: Annals of Oncology. 2011 ; Vol. 22, No. 5. pp. 1154-1163.
@article{e04cf7ca98d1485ebe2e3ed31263e676,
title = "Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)",
abstract = "Background: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). Patients and methods: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. Results: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). Conclusion: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.",
keywords = "Limited disease, Neurocognitive evaluation, Phase III clinical trial, Prophylactic cranial irradiation, Quality of life, Small-cell lung cancer",
author = "{Le P{\'e}choux}, C. and A. Laplanche and C. Faivre-Finn and T. Ciuleanu and R. Wanders and D. Lerouge and R. Keus and M. Hatton and Videtic, {G. M.} and S. Senan and Aaron Wolfson and R. Jones and R. Arriagada and E. Quoix and A. Dunant",
year = "2011",
month = "5",
day = "5",
doi = "10.1093/annonc/mdq576",
language = "English",
volume = "22",
pages = "1154--1163",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

AU - Le Péchoux, C.

AU - Laplanche, A.

AU - Faivre-Finn, C.

AU - Ciuleanu, T.

AU - Wanders, R.

AU - Lerouge, D.

AU - Keus, R.

AU - Hatton, M.

AU - Videtic, G. M.

AU - Senan, S.

AU - Wolfson, Aaron

AU - Jones, R.

AU - Arriagada, R.

AU - Quoix, E.

AU - Dunant, A.

PY - 2011/5/5

Y1 - 2011/5/5

N2 - Background: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). Patients and methods: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. Results: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). Conclusion: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.

AB - Background: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). Patients and methods: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. Results: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). Conclusion: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.

KW - Limited disease

KW - Neurocognitive evaluation

KW - Phase III clinical trial

KW - Prophylactic cranial irradiation

KW - Quality of life

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=79955494691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955494691&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq576

DO - 10.1093/annonc/mdq576

M3 - Article

C2 - 21139020

AN - SCOPUS:79955494691

VL - 22

SP - 1154

EP - 1163

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -